Evaluation of Motexafin gadolinium (MGd) as a contrast agent for intraoperative MRI

H. Hirschberg, Genevieve Wu, S. J. Madsen

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: The characteristics of an ideal contrast agent for use in the intraoperative MRI would be tumor-specificity and intracellular localization, combined with extended tumor enhancement, but with rapid elimination from the blood. The radiation sensitizing properties of Motexafin gadolinium (MGd) have been investigated in a number of clinical trials involving patients with brain metastases. These studies clearly show that MGd is detectable in magnetic resonance images many days following administration. The aim of this experimental study was to test whether Motexafin gadolinium (MGd) could serve as an efficient intraoperative contrast agent avoiding problems that arise with surgically induced intracranial enhancement. Methods: F98 orthotopic brain tumors or surgical lesions were induced in Fisher rats, T1-weighted MRI studies were performed with either a single or multiple daily doses of MGd. The last contrast dose was administered either 7 or 24 hours prior to scanning in both tumor-bearing or surgically-treated animals. All scans were T 1-weighted nce (TR = 495 ms; TE = 1 ms.) with a slice thickness of 1.0 mm. Three tubes containing 2.3, 0.23 and 0.023 mg/mL of MGd (in physiological saline) respectively, were used as standards to calibrate the scans. Results: Animals receiving either 30 or 60 mg/kg MGd i.v. developed clinical signs of impaired motor activity, and increasing lethargy and were euthanized 48 hours after MGd administration due to their poor and deteriorating condition. MGd given i.p. was tolerated up to a dose of 140 mg/kg. Despite multiple dosages and several administration modes (i.p., i.v.) no significant enhancement was observed if the scans were performed 7 or 24 hours following the last MGd dose. Clear enhancement was seen though when the scans were performed 30 min following MGd administration, indicating that the agent was being taken up by the tumor. Scans of necrotic lesions though were positive though 7 hours following MGd injection. MGd scans had no significant enhancement following surgically-induced lesions while scans with conventional contrast agents showed both meningeal and intraparenchymal enhancement. Conclusion: This study suggests that MGd is not sequestered in viable tumor for the necessary time interval required to allow delayed imaging in this model. The agent does seem to remain in necrotic tissue for longer time intervals. MGd therefore would not be suitable as a contrast agent in intraoperative MRI for the detection of remaining tumor tissue during surgery.

Original languageEnglish (US)
Pages (from-to)318-323
Number of pages6
JournalMinimally Invasive Neurosurgery
Volume50
Issue number6
DOIs
StatePublished - Dec 1 2007
Externally publishedYes

Fingerprint

Contrast Media
Neoplasms
motexafin gadolinium
Lethargy
Brain Neoplasms
Motor Activity
Magnetic Resonance Spectroscopy
Clinical Trials
Radiation
Neoplasm Metastasis

Keywords

  • Intraoperative MRI
  • Motexafin
  • Rat brain tumor
  • Surgically-induced contrast

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Evaluation of Motexafin gadolinium (MGd) as a contrast agent for intraoperative MRI. / Hirschberg, H.; Wu, Genevieve; Madsen, S. J.

In: Minimally Invasive Neurosurgery, Vol. 50, No. 6, 01.12.2007, p. 318-323.

Research output: Contribution to journalArticle

@article{0acdea8896fc43d68409dcd8730071b3,
title = "Evaluation of Motexafin gadolinium (MGd) as a contrast agent for intraoperative MRI",
abstract = "Objective: The characteristics of an ideal contrast agent for use in the intraoperative MRI would be tumor-specificity and intracellular localization, combined with extended tumor enhancement, but with rapid elimination from the blood. The radiation sensitizing properties of Motexafin gadolinium (MGd) have been investigated in a number of clinical trials involving patients with brain metastases. These studies clearly show that MGd is detectable in magnetic resonance images many days following administration. The aim of this experimental study was to test whether Motexafin gadolinium (MGd) could serve as an efficient intraoperative contrast agent avoiding problems that arise with surgically induced intracranial enhancement. Methods: F98 orthotopic brain tumors or surgical lesions were induced in Fisher rats, T1-weighted MRI studies were performed with either a single or multiple daily doses of MGd. The last contrast dose was administered either 7 or 24 hours prior to scanning in both tumor-bearing or surgically-treated animals. All scans were T 1-weighted nce (TR = 495 ms; TE = 1 ms.) with a slice thickness of 1.0 mm. Three tubes containing 2.3, 0.23 and 0.023 mg/mL of MGd (in physiological saline) respectively, were used as standards to calibrate the scans. Results: Animals receiving either 30 or 60 mg/kg MGd i.v. developed clinical signs of impaired motor activity, and increasing lethargy and were euthanized 48 hours after MGd administration due to their poor and deteriorating condition. MGd given i.p. was tolerated up to a dose of 140 mg/kg. Despite multiple dosages and several administration modes (i.p., i.v.) no significant enhancement was observed if the scans were performed 7 or 24 hours following the last MGd dose. Clear enhancement was seen though when the scans were performed 30 min following MGd administration, indicating that the agent was being taken up by the tumor. Scans of necrotic lesions though were positive though 7 hours following MGd injection. MGd scans had no significant enhancement following surgically-induced lesions while scans with conventional contrast agents showed both meningeal and intraparenchymal enhancement. Conclusion: This study suggests that MGd is not sequestered in viable tumor for the necessary time interval required to allow delayed imaging in this model. The agent does seem to remain in necrotic tissue for longer time intervals. MGd therefore would not be suitable as a contrast agent in intraoperative MRI for the detection of remaining tumor tissue during surgery.",
keywords = "Intraoperative MRI, Motexafin, Rat brain tumor, Surgically-induced contrast",
author = "H. Hirschberg and Genevieve Wu and Madsen, {S. J.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1055/s-2007-993158",
language = "English (US)",
volume = "50",
pages = "318--323",
journal = "Minimally Invasive Neurosurgery",
issn = "0946-7211",
publisher = "Georg Thieme Verlag",
number = "6",

}

TY - JOUR

T1 - Evaluation of Motexafin gadolinium (MGd) as a contrast agent for intraoperative MRI

AU - Hirschberg, H.

AU - Wu, Genevieve

AU - Madsen, S. J.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Objective: The characteristics of an ideal contrast agent for use in the intraoperative MRI would be tumor-specificity and intracellular localization, combined with extended tumor enhancement, but with rapid elimination from the blood. The radiation sensitizing properties of Motexafin gadolinium (MGd) have been investigated in a number of clinical trials involving patients with brain metastases. These studies clearly show that MGd is detectable in magnetic resonance images many days following administration. The aim of this experimental study was to test whether Motexafin gadolinium (MGd) could serve as an efficient intraoperative contrast agent avoiding problems that arise with surgically induced intracranial enhancement. Methods: F98 orthotopic brain tumors or surgical lesions were induced in Fisher rats, T1-weighted MRI studies were performed with either a single or multiple daily doses of MGd. The last contrast dose was administered either 7 or 24 hours prior to scanning in both tumor-bearing or surgically-treated animals. All scans were T 1-weighted nce (TR = 495 ms; TE = 1 ms.) with a slice thickness of 1.0 mm. Three tubes containing 2.3, 0.23 and 0.023 mg/mL of MGd (in physiological saline) respectively, were used as standards to calibrate the scans. Results: Animals receiving either 30 or 60 mg/kg MGd i.v. developed clinical signs of impaired motor activity, and increasing lethargy and were euthanized 48 hours after MGd administration due to their poor and deteriorating condition. MGd given i.p. was tolerated up to a dose of 140 mg/kg. Despite multiple dosages and several administration modes (i.p., i.v.) no significant enhancement was observed if the scans were performed 7 or 24 hours following the last MGd dose. Clear enhancement was seen though when the scans were performed 30 min following MGd administration, indicating that the agent was being taken up by the tumor. Scans of necrotic lesions though were positive though 7 hours following MGd injection. MGd scans had no significant enhancement following surgically-induced lesions while scans with conventional contrast agents showed both meningeal and intraparenchymal enhancement. Conclusion: This study suggests that MGd is not sequestered in viable tumor for the necessary time interval required to allow delayed imaging in this model. The agent does seem to remain in necrotic tissue for longer time intervals. MGd therefore would not be suitable as a contrast agent in intraoperative MRI for the detection of remaining tumor tissue during surgery.

AB - Objective: The characteristics of an ideal contrast agent for use in the intraoperative MRI would be tumor-specificity and intracellular localization, combined with extended tumor enhancement, but with rapid elimination from the blood. The radiation sensitizing properties of Motexafin gadolinium (MGd) have been investigated in a number of clinical trials involving patients with brain metastases. These studies clearly show that MGd is detectable in magnetic resonance images many days following administration. The aim of this experimental study was to test whether Motexafin gadolinium (MGd) could serve as an efficient intraoperative contrast agent avoiding problems that arise with surgically induced intracranial enhancement. Methods: F98 orthotopic brain tumors or surgical lesions were induced in Fisher rats, T1-weighted MRI studies were performed with either a single or multiple daily doses of MGd. The last contrast dose was administered either 7 or 24 hours prior to scanning in both tumor-bearing or surgically-treated animals. All scans were T 1-weighted nce (TR = 495 ms; TE = 1 ms.) with a slice thickness of 1.0 mm. Three tubes containing 2.3, 0.23 and 0.023 mg/mL of MGd (in physiological saline) respectively, were used as standards to calibrate the scans. Results: Animals receiving either 30 or 60 mg/kg MGd i.v. developed clinical signs of impaired motor activity, and increasing lethargy and were euthanized 48 hours after MGd administration due to their poor and deteriorating condition. MGd given i.p. was tolerated up to a dose of 140 mg/kg. Despite multiple dosages and several administration modes (i.p., i.v.) no significant enhancement was observed if the scans were performed 7 or 24 hours following the last MGd dose. Clear enhancement was seen though when the scans were performed 30 min following MGd administration, indicating that the agent was being taken up by the tumor. Scans of necrotic lesions though were positive though 7 hours following MGd injection. MGd scans had no significant enhancement following surgically-induced lesions while scans with conventional contrast agents showed both meningeal and intraparenchymal enhancement. Conclusion: This study suggests that MGd is not sequestered in viable tumor for the necessary time interval required to allow delayed imaging in this model. The agent does seem to remain in necrotic tissue for longer time intervals. MGd therefore would not be suitable as a contrast agent in intraoperative MRI for the detection of remaining tumor tissue during surgery.

KW - Intraoperative MRI

KW - Motexafin

KW - Rat brain tumor

KW - Surgically-induced contrast

UR - http://www.scopus.com/inward/record.url?scp=39149131672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149131672&partnerID=8YFLogxK

U2 - 10.1055/s-2007-993158

DO - 10.1055/s-2007-993158

M3 - Article

C2 - 18210352

AN - SCOPUS:39149131672

VL - 50

SP - 318

EP - 323

JO - Minimally Invasive Neurosurgery

JF - Minimally Invasive Neurosurgery

SN - 0946-7211

IS - 6

ER -